Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication
D. Heather Watts(National Institutes of Health), Coleen K. Cunningham(Duke Medical Center), Mary Culnane(National Institute of Allergy and Infectious Diseases), Marie‐Louise Newell(University of Cape Town), Kathleen A. Kaiser(Frontier Science & Technology Research Foundation), Lynne Mofenson(Harvard University), Angela E. Scheuerle, Jean-François Delfraissy(Agence Nationale de Recherches sur le Sida et les Hépatites Virales), Laurent Mandelbrot(Hôpital Cochin), Kenneth Stanley(Harvard University Press), Sharon Huang(FuelCell Energy (United States))
Cited by 40
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010
|The Lancet Global Health|2013|861
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
|The Lancet|1999|667
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653